Determination of Cystatin C Level in a Sample of Patients with Chronic Kidney Disease

Maryam Noman  Salman; Ashwak Jasim kzar; Alaa S.  Hamzah

doi:10.51173/jt.v4i33.520

Authors

Maryam Noman Salman Medical Laboratory Science Technology, Medical City Baghdad Teaching Hospital, Iraqi Ministry of Health, Iraq
Ashwak Jasim kzar College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq
Alaa S. Hamzah College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq

DOI:

https://doi.org/10.51173/jt.v4i33.520

Keywords:

CKD, Polycystic, Cystatin C, GFR

Abstract

Chronic kidney disease (CKD) effects around one-third of the population and is frequently under recognized by patients and clinicians. GFR of less than 60 mL/min/1.73 m2, A minimum of 30 mg of albuminuria per 24 hours, Hematuria or structural abnormalities are signs of kidney damage such like polycystic kidney disease or dysplastic kidneys that persists for more than 3 months. The purpose of this research was to examine the efficacy of cystatin C as a measure of renal function in individuals. Cystatin C, Creatinine, urea, and uric acid levels were measured in 225 blood samples (150 patients and 75 controls). Cystatin C was measured as enzymatic link absorbance assay and the measurements of urea, creatinine, and uric acid were performed using the Cobas c311. Cystatin C levels, urea, serum creatinine, and uric acid were found to show high significant differences (p <0.01) between the patient and control. Cystatin C is useful to detect individuals with CKD who show a little reduction in GFR as compared to serum creatinine. Serum Cystatin C, urea, uric acid, and Creatinine levels all rise as eGFR falls. Serum Cystatin C could be utilized to evaluate people who have poorly managed diabetes mellitus or high blood pressure when the serum creatinine level is inconclusive.

Downloads

Download data is not yet available.

References

Levey, AS., Becker ,C., Inker LA. (2015).Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. Jama, 313(8):837-46.

Sabanayagam, C., Chee, ML., Banu, R., Cheng, C.Y, Lim, SC., Tai, E.S., et al. (2019).Association of diabetic retinopathy and diabetic kidney disease with all-cause and cardiovascular mortality in a multiethnic Asian population. JAMA network open, 2(3):e191540-e.

Sterner, N., Nilsson, H., Rosen, U., Lila, B. & Sundkvist, G. (1997). Relationships among glomerular filtration rate, albuminuria, and autonomic nerve function in insulin-dependent and non-insulin-dependent diabetes mellitus. Journal of diabetes and its complications, 11, 188-193.

Mcmanus, M. S. & Wynter-Minot, S. (2017). Guidelines for chronic kidney disease: Defining, staging, and managing in primary care. The Journal for Nurse Practitioners, 13, 400-410.

Eknoyan, G,. Lameire, N., Eckardt, K., Kasiske, B., Wheeler, D., Levin, A., et al. (2013).KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int,3(1):5-14.

Hayn, M., Blötz, A., Rodríguez, A., Vidal, S., Preising, N., et al. (2021).Natural cystatin C fragments inhibit GPR15-mediated HIV and SIV infection without interfering with GPR15L signaling. Proceedings of the National Academy of Sciences,118(3).

ShiIpak, M. G., Mattes, M. D. & Peralta, C. A. (2013). Update on cystatin C: incorporation into clinical practice. American Journal of Kidney Diseases, 62, 595-603

Grubb AO. (2000). Cystatin C – properties and use as a diagnostic marker. Adv Clin Chem.; 35:63–99.

Westhuyzen J. (2006). Review: Cystatin C: a promising marker and predictor of impaired renal function. Ann Clin Lab Sci Autumn.;36(4):387-94.

Sandilands, E.A., Dhaun, N., Dear, J.W., Webb, D.J. (2013).Measurement of renal function in patients with chronic kidney disease. British journal of clinical pharmacology,76(4):504-15.

Dsa, J., Shetty, S., Bhandary, R.R. and Rao, A.V., (2017). Association between serum cystatin C and creatinine in chronic kidney disease subjects attending a tertiary health care center. Journal of Clinical and Diagnostic Research: JCDR, 11(4), p.BC09.

Kashani, K., Rosner, M. H. & Ostermann, M. (2020). Creatinine: from physiology to clinical application. European journal of internal medicine, 72, 9-14.

Clarke, W. (2017). Mass spectrometry in the clinical laboratory: Determining the need and avoiding pitfalls. Mass spectrometry for the clinical laboratory. Elsevier

Perrone, R.D., Madias, NE., Levey, A.S. (1992).Serum creatinine as an index of renal function: new insights into old concepts. Clinical chemistry,38(10):1933-53.

Brown, AC. (2017).Kidney toxicity related to herbs and dietary supplements: Online table of case reports. Part 3 of 5 series Food and Chemical Toxicology,107:502-19.

Kiapidou, S., Liava, C., Kalogirou, M., Akriviadis, E., Sinakos, E. (2020).Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know Annals of hepatology,19(2):134-44.

Seronie -VivIen, S., Delanaye, P., Pieroni, L., Mariat, C., Froissart, M. & Cristol, J.-P. (2008). CystatinC current position and future prospects. Clinical chemistry and laboratory medicine, 46, 1664-1686.

De, S., Roy, A. (2017).Hemodialysis Membranes: For Engineers to Medical Practitioners: CRC Press.3

Rajendiran, S. & Dhiman, P. (2019). Biochemistry Practical Manual-E-Book, Elsevier Health Sciences.

Vanholder, R., Gryp, T., Glorieux, G. (2018).Urea and chronic kidney disease: the comeback of the century?(in uraemia research). Nephrology Dialysis Transplantation,33(1):4-12.

Ndrepepa, G. (2018). Uric acid and cardiovascular disease. Clinical chemical acta, 484, 150-163.

Feig DI. (2009). Uric acid: a novel mediator and marker of risk in chronic kidney disease Current Opinion in Nephrology and Hypertension, Vol.18, No.6, (November 2009), pp.526-530, ISSN 1062-4821.

Sato, Y., Feig, D.I., Stack, A.G., Kang, D.H., Lanaspa, M.A., Ejaz, A.A., et al. (2019).The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nature Reviews Nephrology,15(12):767-75.

Zhang, Q.L., Rothenbacher, D.(2008).Prevalence of chronic kidney disease in population-based studies: systematic review. BMC public health,8(1):1-13.

Oh, S.H., Kim, H.Y., Oak, C.Y, Kim, M.J, Kim, C.S, Choi, J.S., et al. (2010).Prevalence and factors of chronic kidney disease. Korean J Nephrol,29(29):441-9.

Xu, S., Li, Y.C., Chen, C.X. (2020).The Prevalence of Chronic Kidney Disease in Hypertensive Patients in Primary Care in Hong Kong: A Cross-Sectional Study.

Goldberg, I., Krause, I. (2016).The role of gender in chronic kidney disease. Emj,1(2):58-64.

Chang, P.Y., Chien, L.N., Lin, Y.F., Wu, M.S., Chiu, W.T., Chiou, H.Y.(2016). Risk factors of gender for renal progression in patients with early chronic kidney disease. Medicine,95(30).

Lin, Y.L, Chang, I., Liou, H.H., Wang, C.H., Lai, Y.H., Kuo, C.H., et al.(2021). Serum indices based on creatinine and cystatin C predict mortality in patients with non-dialysis chronic kidney disease. Scientific reports,11(1):1-10.

Tapper, M., McGrowder, D.A., Dilworth, L., Soyibo, A. (2021).Cystatin C, vitamin D and thyroid function test profile in chronic kidney disease patients. Diseases,9(1):5.

Kim, H.J., Kim, T.E., Han, M., Yi, Y., Jeong, J.C., Chin, H.J., et al. (2021).Effects of blood urea nitrogen independent of the estimated glomerular filtration rate on the development of anemia in non-dialysis chronic kidney disease: The results of the KNOW-CKD study. PloS one,16(9):e0257305.

Nakayama, S., Satoh, M., Tatsumi, Y., Murakami, T., Muroya, T., Hirose, T., et al. (2021).Detailed association between serum uric acid levels and the incidence of chronic kidney disease stratified by sex in middle-aged adults. Atherosclerosis,330:107-13.

Srivastava, A., Kaze, A.D., McMullan, C.J., Isakova, T., Waikar,S.S. (2018).Uric acid and the risks of kidney failure and death in individuals with CKD. American Journal of Kidney Diseases,71(3):362-70.

Pasala, S., Carmody, J.B. (2017).How to us serum creatinine, cystatin C and GFR. Archives of Disease in Childhood-Education and Practice,102(1):37-43.

Murty, M.S.N., Sharma, U.K., Pandey, V.B. and Kankare, S.B., 2013. Serum cystatin C as a marker of renal function in detection of early acute kidney injury. Indian journal of Nephrology, 23(3), p.180.

Laterza, O.F., Price, C.P., Scott, M.G.( 2002).Cystatin C: an improved estimator of glomerular filtration rate? Clinical chemistry,48(5):699-707.

Benoit, S.W., Ciccia, E.A., Devarajan, P.(2020).Cystatin C as a biomarker of chronic kidney disease: latest developments. Expert review of molecular diagnostics,20(10):1019-26.

Ide H, Iwase M, Fujii H, et al. (2017). Comparison of cystatin C- and creatinine-based estimated glomerular filtration rates for predicting all-cause mortality in Japanese patients with type 2 diabetes: the Fukuoka diabetes registry. Clin Exp Nephrol.;21 (3):383–390.

Gharaibeh KA, Hamadah AM, El-Zoghby ZM, et al. (2018). Cystatin C predicts renal recovery earlier than creatinine among patients with acute kidney injury. Kidney Int Rep.;3(2):337–342.